Chiesi Farmaceutici completed the acquisition of Amryt Pharma for $1.48bn.

Chiesi Farmaceutici, an international, research-focused biopharmaceuticals and healthcare group, completed the acquisition of Amryt Pharma, a global, commercial-stage biopharmaceutical company, for $1.48bn. "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development. Amryt has unique and clinically differentiated products and additional promising drugs in its pipeline, and, as a benefit corporation certified B Corp, Chiesi has a patient-centric and sustainable model in place to make these treatments available to even more patients who need them. As of today, we are officially joining our forces to bring hope to people in need and look forward to this new chapter in our collective journey," Giacomo Chiesi, Chiesi Head of Global Rare Diseases.